2018 Guest Speakers

Embassy Suites by Hilton – Philadelphia Airport
9000 Bartram Avenue, Philadelphia, Pennsylvania  19153  USA
TEL:  +1 – 215 – 365-4500   *   FAX:  +1 – 215 – 365 – 3195

 

Dr. Mark Wilcox, M.D., FRCPath, Conference Chair, serves as a Consultant Microbiologist, Head & Professor of Medical and Academic Lead of Pathology/Clinical Director of Pathology, at the Leeds Teaching Hospitals (LTHT). Dr. Wilcox is a Professor of Medical Microbiology at the University of Leeds at their Institute of Biomedical and Clinical Sciences and is the lead on Clostridium difficile for Public Health England in the UK. Dr. Wilcox serves as the Principal/UK Investigator for several clinical trials of new anti-infective drugs and has provided clinical advice as part of the FDA/EMA submissions for the approval of several novel antimicrobial agents. He was the Director of Infection Prevention, Infection Control Doctor and Clinical Director of Pathology at LTHT. He serves as Assistant Editor of the Journal of Antimicrobial Chemotherapy and Member of Council of the British Society of Antimicrobial Chemotherapy. Prof. Wilcox serves as a Member of the Department of Health’s Antimicrobial Resistance and Healthcare Associated Infection (ARHAI) Committee and an Advisor to the UK Healthcare Commission, the Medicines and Healthcare products Regulatory Agency, the EPIC project on infection control issues, the Health Technology Assessment (HTA) programme on Healthcare Associated Infection and the European Centre for Disease Control. Dr. Wilcox serves as a Member of UK, European and US working groups on Clostridium difficile infection.

Mark Wilcox, MD joins fellow Conference Chair, Dale Gerding, MD, FACP, FIDSA and world-renowned topic experts to discuss the burden of C. difficile infections with the risk factors pertaining to current and emerging treatment options along with the importance of applying evidence-based clinical approaches to the prevention of a C. difficile infection (CDI), one of the leading community and healthcare-associated infections, Microbiome research, and much more.
Presentation Topic:  TBA

gerdingphotoDale Gerding, MD, FACP, FIDSA
Dr. Gerding, MD, FACP, FIDSA, Conference Chair, Professor of Medicine at Loyola University Chicago Stritch School of Medicine in Maywood, Illinois and Research Physician at the Edward Hines Jr. VA Hospital. Prior to his present position Dr. Gerding was Chief of Medicine at VA Chicago, Lakeside Division, and Professor of Medicine at Northwestern University Feinberg School of Medicine. He is an infectious diseases specialist and hospital epidemiologist, past president of the Society for Healthcare Epidemiology of America and past chair the antibiotic resistance committee of SHEA. He is a fellow of the Infectious Diseases Society of America and past Chair of the National and Global Public Health Committee and the Antibiotic Resistance Subcommittee of IDSA.Presentation Topic:  TBA

drpaulfeuerstadt Paul Feuerstadt, MD, FACG
Dr. Feuerstadt, MD, FACG,  is a Native of Long Island, New York.
Dr. Feuerstadt attended the University of Pennsylvania where he earned his Bachelor of Arts degree in Biology, with distinction in research and graduated Summa Cum Laude. Following completion of his undergraduate training,
Dr. Feuerstadt attended the Weill Medical College of Cornell University in Manhattan, New York where he earned his Medical Doctor degree and stayed at New York Presbyterian Hospital/Weill Cornell medical center for his internship and residency in Internal Medicine. Following completion of his residency Dr. Feuerstadt then moved on to the Montefiore Medical Center in the Bronx, NY for his clinical fellowship training.His areas of interest include ischemic diseases of the gut and chronic diarrheal syndromes with a specific focus on C.diff. infections. Dr.Feuerstadt is affiliated with St. Raphael campus of Yale-New Haven Hospital, Yale-New Haven Hospital and Milford Hospital seeing outpatients in his offices in Hamden and Milford, CT
Presentation Topic: TBA

Joe Martin
Joe Martin, Executive Director, Pennsylvania Health Care Cost Containment Council (PHC4) Mr. Martin, who joined PHC4 in 1991, was appointed to the Executive Director position on November 5, 2009. In this role, he provides leadership to a professional and technical staff of 28 and is responsible for overseeing all agency operations, including the planning, directing, coordinating and executing of all PHC4 initiatives. He also works with a 25-member Council to set policy and work priorities as well as to plan and implement the future direction for PHC4.
Presentation Topic: TBA

Edmond A. Hooker, MD, DrPH
Dr. Hooker, MD, DrPH, received his B.S. degree from Hampden-Sydney College in Virginia. He earned his M.D. degree from Eastern Virginia Medical School. He then completed his residency training in Emergency Medicine at the University of Louisville. As a full-time faculty member at the University of Louisville from 1991 until 1996, Dr. Hooker served as an Associate Professor and Director of Resident Research. He was very active in brain trauma and stroke research. After leaving the University of Louisville, he worked in Virginia and was on faculty at the University of Virginia. He moved to Cincinnati in 1998. Dr. Hooker works clinically in the emergency department at the University of Cincinnati Hospital, serves as Residency Research Director, and directs the Clinical Research Coordinator’s program. Dr. Hooker serves as a medical advisor to Trinity Guardion. Since 2003, Dr. Hooker has been teaching in the Department of Health Services Administration at Xavier University. In the spring of 2007, Dr. Hooker earned his Doctorate in Public Health from the University of Kentucky. In 2015, he was promoted to Professor. Dr. Hooker continues to be active in emergency medicine and public health research.
Presentation Topic: UPDATES —Mattresses and Hospital Beds as a Vector For
Spreading Clostridium difficile”

Stuart B. Johnson, MD,FIDSA, DTM&H
Dr. Johnson, MD,FIDSA, DTM&H, Professor, Department of Medicine, Stritch School of Medicine, Loyola University, Chicago, IL. Dr. Stuart Johnson, MD is a Professor of Medicine at Loyola University Stritch School of Medicine at Loyola University Medical Center and a Researcher at the Hines VA Hospital, Chicago, Illinois. His main research interest and focus has involved the epidemiology pathogenesis, and treatment of Clostridium difficile infection. He is actively studying variant strains of C. difficile and the role of the various toxins in the pathogenesis of C. difficile disease. His clinical experience in the treatment of patients with recurrent CDI has translated into studies helping to define optimal management of these infections, including the utility and pitfalls of alternative treatment agents. He is currently the Principal Investigator of a multi-center study with the VA Healthcare system designed to define optimal management of early
recurrences of CDI.
Presentation Topic:  TBA

khanna_sahil_13ap-2

Sahil Khanna, MD
Dr. Khanna, MD is an Assistant Professor of Medicine in the Division of Gastroenterolgy and Hepatology at Mayo Clinic, Rochester, MN.  His completed Medical School at the All India Institute of Medical Sciences, New Delhi; followed by Post Doctoral Research at University of California, San Diego, CA; residency in Internal Medicine and Fellowship in Gastroenterology and Hepatology at Mayo Clinic, Rochester, MN before joining the Faculty.  Dr. Khanna has completed Masters in Clinical and Translational Sciences during his fellowship. His research and clinical interests include Epidemiology, Outcomes and Emerging Therapeutics for Clostridium difficile infection, an arena in which he has had numerous publications and presentations.  He is directing the C. difficile Clinic, Fecal Microbiota Transplantation program and C. difficile related Clinical Trials at the May Clinic, Rochester, MN.
Presentation Topic:   TBA

Nicola Petrosillo, MD, FESCMID
Dr. Petrosillo, MD,FESCMID earned a degree of Doctor in Medicine and Surgery from the University “La Sapienza” in Rome, Italy in 1977; in the same University, he became specialist in Infectious Diseases (1981) and in Internal Medicine (1985). In 1981, he became hospital infectious diseases registrar and in 1999 Director of an Infectious Diseases Division at the National Institute for Infectious Diseases “Lazzaro Spallanzani” of Rome, Italy.He is fellow of the Pulmonary Vascular Research Institute and leader of the international task-force for pulmonary hypertension associated with HIV, since 2007. He is member of the Professional Affairs SubCommittee on Infectious Diseases and member of the Advisory Board of the Trainee Association of ESCMID. Additionally, he is Professor of Infectious Diseases at the Medical School of Specialization in Hygiene of the Tor Vergata University, Rome, and presently Director, Clinical & Research Department for Infectious Diseases National Institute for Infectious Diseases “Lazzaro Spallanzani”, IRCCS.
Presentation Topic:   TBA

Norman B. Javitt, MD, Ph.D.
Dr. Norman Javitt, MD is a research doctor in New York, New York. He received his medical degree from Duke University School of Medicine and has been in practice for more than 20 years. Education and Medical Training: Mount Sinai School of Medicine ,Residency , Internal Medicine,Mount Sinai School of Medicine Residency , Internal Medicine, Mount Sinai School of Medicine ,Internship , Transitional Year Duke University School of Medicine Medical School. Elected Member The American Society for
Clinical Investigation, 1969.
PresentationTopic:    TBA

Nick Van Hise, PharmD, BCPS
Nick Van Hise, PharmD, received a Bachelor of Science from Bradley University in Peoria, IL and his Doctorate of Pharmacy from Union University School of Pharmacy in Jackson, TN.Dr. Van Hise then went on to do an infectious disease residency and become board certified in pharmacoltherapy and infectious disease. Dr. Van Hise has been published in various scientific journals, includng the New England Journal of Medicine, Clinical Infectious Diseases, and the Journal of Clinical Neuropharmacology.

 

C. diff. Survivors
Mr. Roy Poole and Mrs. Kathy Bischoff –  C. diff. Survivors — join us to share their personal C. difficile infection journey; The signs, symptoms, treatments, with the physical, mental, and psycho-social changes endured from this life-threatening infection and how each recurrent C. difficile infection (rCDI) impacted their lives.
Presentation Topic: “A C. diff. Survivor’s Journey.”

simonheadshot-001

Simon M. Cutting, Ph.D.
Professor Cutting of Molecular Microbiology at Royal Holloway, University of London is a bacterial geneticist with over 25 years of experience with Bacillus since graduating from Oxford University with a D. Phil in 1986. His D.Phil was on understanding the genetic control of spore formation in Bacillus Clostridium difficile.. His other expertise is in the use of Bacillus spores as probiotics and has a number of contracts and consultancies with European and US companies in the food and feed sectors.
Presentation Topic:    TBA

Christopher R. Polage, MD
Dr. Polage is Assistant Professor of Clinical Pathology at Duke University, Previous Director of Clinical Microbiology Laboratory, Department of Pathology and Laboratory Medicine at UC Davis Medical Center. Dr. Polage received a Bachelor degree in Biology and Doctor of Medicine from the University of New Mexico. Clinical Internship in Internal Medicine at University of Colorado and University of New Mexico. Clinical Internship in Internal Medicine at University of Colorado and residency training in anatomic and clinical pathology at the University of Utah receiving an award for research involving the identification of non-fermenting Gram negative bacteria via Amplication and sequencing of 16s rDNA.  He stayed in Utah to complete a two year fellowship in Medical Microbiology at ARUP Laboratories, serving as Acting Assistant Medical Director of Mycobacteriology.  Dr. Polage’s main clinical interests are Utilization of Laboratory Testing for diagnosis of infectious diseases, Diagnosis of viral CNS and respiratory syndromes, Diagnosis of Infection in the setting of colonizing microbial fora, Access to laboratory testing and diagnosis in resource limited settings, Research interests in developing methods to improve the rapidity and clinical impact of infectious disease testing, application of non-culture based methods, identification of markers of pathogenicity, virulence and clinical prognosis.  Presentation Topic:  TBA

Elaine Wang, MD, FIDSA
Dr. Wang, MD, FIDSA graduated from McGill University medical school and received a MSc in Clinical Epidemiology from McMaster University.  She was a practicing pediatric infectious disease specialist at The Hospital for Sick Children reaching a rank Associate Professor in Pediatrics at the University of Toronto, an appointment that she maintains.  She subsequently joined industry to pursue the development of a RSV vaccine. She has worked at Boehringer-Ingelheim, first in clinical development in Virology and Immunology, and then in medical affairs working on their treatment for an orphan disease, idiopathic pulmonary disease.  She has joined
Seres Therapeutics to work on their proprietary microbiome-based interventions.
Presentation Topic:    TBA


Maureen Spencer, RN, M.Ed.
Maureen Spencer, RN, M.Ed. has been board certified in infection control (CIC) for over 30 years and is currently the Director, Clinical Implementation at Accelerate Diagnostics, providing educational and consultative services to the sales and marketing teams in the US. She was previously the Corporate Director, Infection Prevention for Universal Health Services in King of Prussia, PA, Infection Control Manager at New England Baptist Hospital, Director Infection Control Unit at Mass General Hospital and other Boston hospitals in a career that has spanned
over 40 years.
Presentation Topic:   TBA

Joseph Sliman, MD,MPH
Dr. Sliman, MD, MPH, is Chief Medical Officer and joined Synthetic Biologics in January 2013 as the Senior Vice President, Clinical & Regulatory Affairs. In this position, Dr. Sliman will be responsible for the design and implementation of all aspects of clinical development, including clinical trials, and will lead the Company’s regulatory initiatives. During his service in the United States Navy, Dr. Sliman led the U. S. Pacific Fleet disease surveillance programs, including influenza surveillance, preparedness, and prevention, as well as communicable disease and injury surveillance and prevention and health policy development. Dr. Sliman earned an M.D. from the Uniformed Services University, a Master’s Degree in Public Health from the Johns Hopkins University School of Public Health, and a B.S. in Molecular and Cell Biology, with Honors in Biology, from Pennsylvania State University
Presentation Topic:    TBA

Stephen Marcella, MD
Dr. Marcella, MD is a clinician trained in internal medicine and pediatrics.  After serving in the National Health Service for 4 years and then as a faculty member of a primary care residency, he became interested in clinical epidemiology. Having obtained an MPH from Rutgers in NJ, he spent the next 15 years doing epidemiology research, teaching medical and graduate students, supervising medicine residents, and seeing patients in a federally qualified health care clinic associated with the Robert Wood Johnson Medical School. His research interests have focused largely on prevention and screening and he directed a large NIH-funded study of PSA testing and prostate cancer mortality in New Jersey. He continues to teach at the Rutgers School of Health as an adjunct professor.  For the last four years, Steve has been working as a director in outcomes research at Merck. In the last two years, he has been working on quantifying the burden of illness from CDI and recurrent CDI as well as the health economic data behind Merck’s new product that reduces the recurrence of CDI. This work incorporates elements of health economics, epidemiology, and real world evidence.
Presentation Topic: “The Health Economics and Quality Of Life Implications Of
a Clostridium difficile Infection.

Barley Chironda,, RPN, CIC.
Barley Chironda, a Nurse, is the Social Media Manager of IPAC Canada and the Past President of IPAC- GTA. He is also the National Healthcare Sales Director and Infection Control Specialist with Clorox Canada. He is certified in Infection prevention and control (CIC™) and has worked extensively as in Infection Control. He is typically found engaged in motivating hospital staff, patients and the public on proper infection prevention practices. His roles allow great participation in quality improvement interventions related to patient and public safety. Therefore Barley has been an integral to the successful decline in Clostridium difficile infections through implementing innovative technology and quality improvement behavioural change. He takes pride in sharing information via social media and is often engaging the public on Twitter™ and LinkedIn™, partaking in resource distribution related to innovative and novel Infection prevention strategies. Barley also volunteers as the Infection Control Specialist with the C Diff Foundation.
Presentation Topic:  TBA

Guest Speakers Will Be Added Monthly Until April 2018 – for Final Program.

MEDIA INFORMATION:

The C Diff Foundation welcomed members of the Media to the

6th Annual International C. diff. Awareness Conference and Health EXPO

November 8 and 9, 2018 at the Embassy Suites by Hilton Philadelphia PA

Qualifications and guidelines
Registration is complimentary for professional journalists attending the conference
to provide editorial coverage and who meet the eligibility criteria.

Please contact the C Diff Foundation  info@cdifffoundation.org

 

Follow us on Twitter  

#Cdiff 2018


@cdiffFoundation